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Background: Patients suffering from brain tumours such as glioblastoma and medulloblastoma have poor prognosis
with a median survival of less than a year. Identifying alternative molecular targets would enable us to develop different
therapeutic strategies for better management of these tumours.
Methods: Glioblastoma (MO59K and KNS60) and medulloblastoma cells (ONS76) were used in this study. Telomerase
inhibitory effects of MST-312, a chemically modified-derivative of epigallocatechin gallate, in the cells were assessed using
telomere repeat amplification protocol. Gene expression analysis following MST-312 treatment was done by microarray.
Telomere length was measured by telomere restriction fragments analysis. Effects of MST-312 on DNA integrity were
evaluated by single cell gel electrophoresis, immunofluorescence assay and cytogenetic analysis. Phosphorylation status
of DNA-PKcs was measured with immunoblotting and effects on cell proliferation were monitored with cell titre glow
and trypan blue exclusion following dual inhibition.
Results: MST-312 showed strong binding affinity to DNA and displayed reversible telomerase inhibitory effects in brain
tumour cells. In addition to the disruption of telomere length maintenance, MST-312 treatment decreased
brain tumour cell viability, induced cell cycle arrest and double strand breaks (DSBs). DNA-PKcs activation was
observed in telomerase-inhibited cells presumably as a response to DNA damage. Impaired DNA-PKcs in MO59J cells
or in MO59K cells treated with DNA-PKcs inhibitor, NU7026, caused a delay in the repair of DSBs. In contrast, MST-312
did not induce DSBs in telomerase negative osteosarcoma cells (U2OS). Combined inhibition of DNA-PKcs and
telomerase resulted in an increase in telomere signal-free chromosomal ends in brain tumour cells as well.
Interestingly, continual exposure of brain tumour cells to telomerase inhibitor led to population of cells, which displayed
resistance to telomerase inhibition-mediated cell arrest. DNA-PKcs ablation in these cells, however, confers higher cell
sensitivity to telomerase inhibition, inducing cell death.
Conclusions: Efficient telomerase inhibition was achieved with acute exposure to MST-312 and this resulted in subtle
but significant increase in DSBs. Activation of DNA-PKcs might indicate the requirement of NHEJ pathway in the repair
telomerase inhibitor induced DNA damage. Therefore, our results suggest a potential strategy in combating brain
tumour cells with dual inhibition of telomerase and NHEJ pathway.
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Brain tumours comprise of a wide variety of subtypes
of which Glioblastoma multiforme and medulloblastoma
are the most common primary malignant brain tumours
in adults and children, respectively. Although current
clinical data show evidence that molecular targeting has
improved the management of brain tumours, prognosis
still remains poor [1,2]. Therefore, the need to discover
alternative approach to improve therapeutic response in
brain tumour patient remains important.
The two most common hallmarks of tumour cells
are their limitless proliferation capacity and sustained
massive genome instability [3]. In normal cells, induc-
tion of DNA damage either by exogenous or endogenous
agents leads to the activation of appropriate DNA dam-
age response (DDR) pathway to ensure immediate repair
and to prevent propagation of cells with highly unstable
genomes. DNA double-strand breaks (DSB) are the most
lethal form of DNA damage and if unrepaired, DSBs
severely threaten not only the integrity of the genome
but also the survival of the organism [4]. The DDR to
DSBs involves activation of homologous recombination
(HR) or non-homologous end joining (NHEJ) pathway
while the latter is the more dominant DSB repair mech-
anism compared to HR in mammalian cells [5-7]. NHEJ
pathway is facilitated by the DNA-dependent protein
kinase (DNA-PK), composed of a catalytic subunit, DNA-
PKcs, and the heterodimeric DNA binding regulatory Ku
complex, Ku70 and Ku86. The Ku heterodimer binds free
DSB ends and recruits DNA-PKcs, which then is activated
by the DNA-bound Ku complex. Artemis, the XRCC4/
ligase IV complex is also recruited to the complex and
serves to catalyse re-ligation of the DNA broken ends.
Studies have shown that inhibition of DNA-PKcs sensi-
tise tumour cells to radiation, suggesting its potential as
a molecular target in cancer therapy [8].
Besides its role in NHEJ pathway, DNA-PKcs also
plays a crucial role in maintaining telomeres [9,10].
Telomeres are nucleoprotein complexes that function to
distinguish the ends of the chromosome from DSBs and
to maintain chromosomal integrity [11]. In normal cells,
telomere length regulates its replication potential. As
cells divide, telomere shortening due to end-replication
problem of conventional DNA polymerase, coupled with
low or absence of telomerase activity, eventually leads
to telomere uncapping, triggering DDR or cell death, if
damage is irreparable [12,13]. In contrast, majority of
tumour cells continue to proliferate, despite harbouring
relatively shorter telomeres compared to normal tissues
due to re-activation of telomerase enzyme [14,15]. Tel-
omerase complex is made up of the reverse transcriptase
catalytic subunit (TERT) and RNA template subunit
(TR) and other associated proteins [16]. Inhibition of
telomerase via genetic alteration using dominant negativehTERT, mutant hTR template [17,18] or pharmacological
inhibitors slows tumour cell growth by triggering telo-
mere shortening and cell death [19,20]. Given the high
level of telomerase activity in brain tumour progression
[21,22], telomerase provides a molecular target in brain
tumour cells.
One major drawback of targeting telomerase is the lag
time needed for telomere erosion-mediated cell death
leading to possible emergence of adaptive response and
resistance mechanisms such as alternative lengthening
of telomeres (ALT) mechanism which allows telomere
maintenances via HR [23,24]. Previously, we have shown
that inhibition of telomerase and DNA repair protein in
mouse embryonic fibroblasts sensitises cells to DNA
damaging agents [25]. Here, we provide evidence that ef-
ficient telomerase inhibition was achieved using MST-
312 in brain tumour cells inducing telomere shortening.
Acute telomerase inhibition in brain tumour cells trig-
gered DSBs, cell cycle arrest and subsequent DDR coupled
with activation of DNA-PKcs. Inhibition of DNA-PKcs
following MST-312 mediated telomere dysfunction leads
to increase cell death in brain tumour cells demon-
strating the potential therapeutic combinations in enhan-
cing telomerase-mediated therapy.
Results
MST-312 reduces telomerase activity and telomere length
in brain tumour cells
Although, previous studies have shown that MST-312
inhibits telomerase activity in tumour cells, its mode of
mechanism is yet to be fully understood in brain tumour
cells. We first treated medulloblastoma cells, ONS76
with MST-312 (0–5 μM) for 48 hours and measured the
levels of telomerase activity. As shown in Figure 1A,
MST-312 inhibited telomerase activity in a dose dependent
manner and approximately 40% decrease in telomerase
activity was observed at 1.0 μM of MST-312. MST-312
treated glioblastoma cells, MO59K and KNS60, also
showed reduction in telomerase activity (Figure 1B). As
there was approximately 50% decrease in telomerase activ-
ity in all the brain tumour cells tested at 1.0 μM MST-312,
subsequent studies were performed using this dose. As tel-
omerase regulation occurs mainly at the level of transcrip-
tion of its two core subunits, TERT and TR [26] we
analysed the expression of TERT and TR following MST-
312 treatment. There were no significant changes in TERT
and TR gene expression (data not shown) or TERT protein
level following 1.0 μM MST-312 treatment for 48 hours
(Figure 1C).
Next, we wanted to determine whether telomerase
inhibition persists following withdrawal of MST-312
in brain tumour cells. To investigate this, we treated
MO59K cells with 1.0 μM MST-312 for 48 hours, after
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Figure 1 MST-312 binds to DNA and inhibits telomerase activity in brain cancer cells. (A) Medulloblastoma cells, ONS76, were treated with
indicated doses of MST-312 for 48 hours and examined for telomerase activity by TRAP assay. (B) Glioblastoma cells, MO59K and KNS60, were
treated with low dose of MST-312 for 48 hours and examined for telomerase activity. (C) Brain tumour cells were treated with 1.0 μM MST-312 for
48 hours and the expression of hTERT was determined by western blot. (D) MO59K cells treated with 1.0 μM MST-312 for 48 hours were grown
in fresh media for 72 hours and telomerase activity was determined. Days refer to the number of recovery days post 48 hours treatment with
1.0 μM MST-312. (E) Genomic DNA was extracted from ONS76 cells and binding affinity of MST-312 to DNA determined with ITC assay. ITC assay
demonstrated that MST-312 has strong binding affinity to DNA (right panel) demonstrated by the increase in the amount of heat released (bond
formation) when normalised with control (left panel). Means and standard errors (SE) from three independent experiments are presented.
*Represents statistically significant (p <0.05) in comparison to the respective DMSO treatments.
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72 hours, telomerase activity in these cells rose back to
95% of basal activity (Figure 1D), indicating that the in-
hibitory effect of MST-312 is not persistent and is revers-
ible. In addition, we revealed using isothermal
calorimetry analysis (ITC) assay that MST-312 has strong
binding affinity to DNA (Figure 1E). Taken together,
these findings suggest that MST-312 probably acts as a
competitive inhibitor to telomerase in brain tumour cells.
Telomere length analysis was subsequently carried out
in brain tumour cells. Given that cell division is neces-
sary for telomere erosion to occur in the absence or
reduced level of telomerase activity, a lower dose of
MST-312 was used so that brain tumour cells are still
able to proliferate while telomerase activity is beingcompromised. The brain tumour cells, MO59K, ONS76
and KNS60, were treated with 0.5 μM MST-312. As
shown in Figure 2A, a decrease of 0.4 to 0.95 kb in telo-
mere length was observed in brain tumour cells after
4 to 5 weeks of MST-312 treatment. The extent of
telomere shortening differed among the various brain
tumour cells tested. The smallest reduction (0.23 kb) in
telomere length was observed in medulloblastoma cells,
ONS76, which had the shortest basal telomere length
(Figure 2A). Glioblastoma cells, KNS60, showed the
largest decrease (0.95 kb) in telomere length. Next,
to examine whether the telomere shortening by the MST
compounds was associated with gradual reduction in cell
proliferation, we measured the cell count using trypan
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Figure 2 MST-312 induces telomere shortening and reduces cell proliferation in brain tumour cells. (A) Total genomic DNA prepared
from MO59K, KNS60 and ONS76 cells treated with 0.5 μM MST-312 for indicated number of days was assessed for telomere length using TRF
assay. (B-D) Cell proliferation capacity in 0.5 μM MST-312 treated brain tumour cells were analysed with trypan blue exclusion assay.
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tumour cells tested.
Effects of MST-312 on DNA integrity and cell cycle
progression
Recent studies have shown that short-term telomerase
inhibition with MST-312 induces DNA damage as mea-
sured by gamma H2AX expression, independent of telo-
mere shortening in primary ependymoma cells [27].
Therefore, we wanted to examine whether the acute
telomerase inhibition affects DNA integrity in brain
tumour cells. Comet assay was first used to measure the
extent of DNA damage following 1.0 μM MST-312 treat-
ment for 48 hours and as summarised in Figure 3A,
there was approximately a two-fold increase in the level
of DNA damage in all the cells tested. We also deter-
mined the phosphorylation of H2AX at serine 139
(γH2AX), a marker for DSBs, and observed significant
increase in the number of γH2AX-positive cells(Figure 3B). There was approximately 19%, 15%, 11%
increase in γH2AX-positive cells in MST-312 treated
MO59K, KNS60 and ONS76 cells as compared to
their respective controls. In contrast, telomerase
-negative osteosarcoma cells (U2OS) (Figure 4C), and
human lung fibroblasts (MRC-5), showed minimal or
lesser extent of increase in γH2AX-positive cells (data
not shown). Next, telomere-dysfunction induced foci
(TIF) analysis was carried following 24 and 48 hours
treatment with 1.0 μM MST-312. Telomerase positive
brain tumour cells, KNS60 and ONS76 showed greater
increase in TIFs as compared to MRC-5 cells
(Figure 3C). There was 12% and 14% increase in
ONS76 and KNS60 in MST-312 treated cells as com-
pared to 4% increase in MRC-5 cells after 48 hours
treatment with MST-312. Given that MST-312 binds to
DNA, it is possible that binding of MST-312 to the
telomeres delays replication of the cells and activation
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Figure 3 (See legend on next page.)
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Figure 3 DNA damage and cell cycle arrest in cells treated with MST-312. (A) The extent of DNA damage in cells treated with 1.0 μM MST-312
for 48 hours represented by tail moment. A significant increase in DNA damage was observed in all the cell types. (B) Extent of double strand breaks
was measured using detection of γH2AX foci and Increase in formation of DSBs in all cell types was observed following 48 hours of 1.0 μM MST-312.
(C) Telomere dysfunction induced foci (TIF) analysis following treatment with 1.0 μM MST-312 for 24 and 48 hours in MRC-5, ONS76 and KNS60 cells.
Significant increase in the number of cells with TIFs (yellow foci) was observed following MST-312 treatment in ONS76 and KNS60 cells compared to
that in MRC-5 cells. Images were captured using a Zeiss Axioplan Imaging fluorescent microscope with 63 × objective and are processed using Adobe
Photoshop CS2 (Adobe Systems Incorporated, USA) for clarity and illustration. (D) Decrease in survival of cells was observed in all cells tested following
MST-312 concentration as indicated for 48 hours. (E) Flow cytometry analysis of cell cycle profiles in MST-312-treated cells. MO59K and KNS60 cells
showed significant increase in G2/M and apoptotic cell population. On the contrary, there was significant increase in G1 population in ONS76 cells
following MST-312 treatment.
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lowing MST-312 treatment, cell cycle progression and cell
survival were evaluated. Consistent with dose-dependent
decrease in telomerase activity (Figure 1A), there was a
dose-dependent decrease in cell viability following MST-
312 treatment (Figure 3D). FACS analysis performed in
brain tumour cells exposed to MST-312 indicated that0
20
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Figure 4 Role of DNA-PKcs in MST-312-induced double strand breaks
foci formation following 1.0 μM MST-312 and/or 10 μM NU7026 treatment
γH2AX (damage) in MST-312 treated cells. Following 24 hours recovery (rep
proficient cells. (B) Protein expression studies following (1.0 μM) MST-312 tre
experiments. *P-value <0.05 when compared to untreated controls. (C-D) Ef
(C) Level of γH2AX foci positive cells following treatment with 1.0 μM MST-3
(D) DNA-PKcs status following 48 hours treatment with 1.0 μM MST-312 andinhibition of cell proliferation was related to cell cycle ar-
rest. At 1.0 μM MST-312 treatment for 48 hours, G2/M
arrest in glioblastoma cells, MO59K and KNS60, and G1
arrest in medulloblastoma cells, ONS76, were observed.
However, there was a significant increase in apoptotic cell
death at 2.0 μM MST-312 in both the glioblastoma cells
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in brain tumour cells. (A) Extent of DSBs was measured as γH2AX
. There was significant increase in the distribution of cells positive for
air) period, the γH2AX level returned to basal level only in DNA-PKcs
atment in MO59K cells. Data represent mean ± SE from 3 independent
fects of combined treatment of MST-312 and NU7026 in U2OS cells.
12 and 10 μM NU7026 in telomerase negative U2OS cells.
/or 10 μM NU7026.
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tumour cells
DNA damage triggers transcriptional changes in cells in
order to maintain genome integrity [28]. Pertinent to
this study, genes involved in cell proliferation and signal-
ling, cell death, DNA damage, telomere and telomerase
homeostasis were evaluated. As shown in Table 1, a dif-
ferential expression pattern was observed among the
brain tumours cells following MST-312 treatment as
compared to their respective controls. For example, in
glioblastoma cells KNS60, there was a decrease in Cyclin B
and Survivin gene expression while an increase in both the
genes was observed in medulloblastoma cells, ONS76. In
addition, the expression of gene coding for interlukin-1
receptor-associated kinase 2 (IRAK2) proteins which acti-
vates nuclear factor kappa-B (NF-kB) was up-regulated in
glioblastoma cells, KNS60, and down-regulated in medul-
loblastoma cells, ONS76.
Although we found minimal changes in TERT or TERC
(data not shown) expression in MST-312 treated brain
tumour cells, which corroborate with the minimal effects
of MST-312 in the TERT protein expression (Figure 1C),
we observed down-regulation in proteins reported to have
roles in telomerase regulation. For example, a decrease in
expression of c-MYC, TIN2, DKC1, and RFC1 genes which
are positive regulators of telomerase, was seen in MST-
312 treated brain tumour cells. There was also a decrease
in expression of Transforming growth factor beta (TGFB),
a multifunctional cytokine that represses TERT expression
via down-regulation on c-myc [29,30]. Even though we
observed down-regulation in expression of MYC gene,
the level of TERT protein and gene expression was not
altered in MST-312 treated brain tumour cells. These
findings suggest that the observed anti-proliferative ef-
fects following MST-312 treatment in brain tumour cells
are via telomerase inhibition rather than TGF-β down-
regulation. More importantly, in both the brain tumour
cells, KNS60 and ONS76, we observed a consistent de-
crease in the expression of gene coding for ATM and
RAD50 proteins, which are involved in HR pathways.
A recent study carried out in telomerase null mice
[31] revealed that peroxisome proliferator-activated re-
ceptor gamma, coactivator 1 alpha and beta (PGC-1α
and PGC-1β, also known as Ppargc1a and Ppargc1b,
respectively) were repressed via p53 dependent manner.
PGC-1α and PGC-1β are two known regulators of mito-
chondrial biogenesis and function and repression of ei-
ther or both decreases mitochondrial biogenesis and
function [32]. From our gene expression data, we ob-
served significant changes in PGC1α or PGC1β in brain
tumour cells. In medulloblastoma cells ONS76, decreased
in expression of PGC1β (p <0.05) was observed following
48 hours MST-312 treatment (Table 1). In contrast, in-
crease in of PGC1α (p < 0.05) was observed in glioblastomacells KNS60. Given the direct link of p53 activation neces-
sary for repression for p53-induced PGC1α and PGC1β,
this differential observation made in our study could be
related to different p53 status in ONS76 (wild type p53)
and KNS60 (mutant p53) cells [33-35].
Lack of DNA-PKcs delays repair of MST-312 induced DSBs
Given the importance of DNA-PKcs in NHEJ, we next
wanted to investigate the role of DNA-PKcs in repair of
DNA damage following telomerase inhibition in brain
tumour cells. To evaluate this, we used glioblastoma
cells, MO59J, which is deficient in DNA-PKcs activity
and MO59K cells, which has wild type DNA-PKcs. We
exposed both the cells to 1.0 μM MST-312 for 48 hours
and allowed for a 24 hour recovery period to determine if
any DSB repair occurred. As shown in Figure 4A, we ob-
served induction of DSBs in both the cell types following
48-hour MST-312 treatment. Interestingly, when DSBs
were evaluated in MO59K and MO59J cells 24 hours
post MST-312 treatment, MO59J cells failed to repair the
DSBs induced by MST-312 as efficiently as in MO59K
cells. This finding was further corroborated when inhib-
ition of DNA-PKcs activity in MO59K with NU7026 did
not show a similar reduction in DSBs level as observed in
MO59K cells (Figure 4A). Then we examined if DNA-
PKcs was activated following MST-312 treatment in brain
tumour cells. Phosphorylation at Serine 2056 in response
to DSBs in vivo is important for NHEJ pathway [36]. As
shown in Figure 4B, there was a substantial increase in the
levels of phospho-DNA-PKcs (Ser-2056) after 48 hour-
treatment with 1.0 μM MST-312 in telomerase-positive
MO59K cells, unlike in telomerase- negative U2OS cells
(Figure 4D). Hence, these findings demonstrate that DNA-
PKcs is involved in the repair of DSBs following MST-312
treatment in glioblastoma cells.
DNA-PKcs inhibition increases telomere dysfunction and
cell death in glioblastoma cells
Next, we investigated whether DNA-PKcs inhibition
sensitises glioblastoma cells to MST-312 induced cell
death. MO59K cells were pre-treated with 10 μM of
NU7206 for two hours followed by a 48-hour treatment
with 1.0 μM of MST-312. As shown in Figure 5A, inhib-
ition of DNA-PKcs alone led to 45% reduction in cell
survival as compared to control cells. This reduction
was greater than that in MST-312 treated cells (31%).
More importantly, dual inhibition of DNA-PKcs and tel-
omerase led to 65% reduction in terms of cell survival
(Figure 5A). To assess further the impact of dual inhib-
ition on glioblastoma cells proliferation, telomerase and
DNA-PKcs were inhibited for 1 week in MO59K cells.
As shown in Figure 5C, chronic treatment in NU7026
and MST-312 led to synergistic increase in cell death in
glioblastoma cells. Cytogenetic analysis was also carried
Table 1 List of differentially expressed genes following
MST-312 treatment in brain tumour cells
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Functional groupings/clusters of differentially expressed following 48 hours
treatment with telomerase inhibitor (1.0 μM MST-312) in glioblastoma cells
KNS60 and medulloblastoma cells ONS76. List of selected genes that showed
significant fold changes (P <0.05) in at least in one of the tumour cells following
MST-312 treatment (*) as compared to their respective controls. Data indicates
statistically significant (bold) compared with respective untreated controls.
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ition on chromosomal integrity. As shown in Figure 5D,
there was minimal increase in chromosomal fusion but
approximately 5-fold increase in the frequency of signal-
free telomeric ends of chromosomes in cells treated with
both NU7026 and MST-312 as compared to untreated
control cells.
Inhibition of DNA-PKcs impair cell proliferation in tel-
omerase inhibited brain tumour cells
Our findings in MO59K cells prompted us to investigate
the effects of DNA-PKcs inhibition in other telomerase
inhibited brain tumour cells. Thus, we first determined
the phosphorylation status of DNA-PKcs in KNS60
and ONS76 cells following telomerase inhibition and
observed activation of DNA-PKcs only in KNS60 cells
(Figure 6A). This may be due to lesser extent of DNA
damage in ONS76 cells as compared to KNS60 cells
(Figure 3A) leading to cell cycle arrest instead of cell
death as observed in KNS60 (Figure 3D-E). Interestingly,
there was significant reduction in the level of DNA-PKcs
activity in dual inhibited brain tumour cells (Figure 6A)
leading to increased growth retardation in MO59K (65%),
KNS60 (61%) and ONS76 cells (57%) (Figure 6B).
It is suggested that prolonged exposure to telomerase
inhibitors may also give rise to population of cells that
shows resistance to telomerase inhibition therapy. As
shown above, continual treatment with low dose of
MST-312 leads to telomere shortening by 28–33 days
in brain tumour cells (Figure 2A). Thus, to test the
impact of continuous exposure to telomerase inhibitors,
brain tumour cells were treated with 0.5 μM of MST-312
for 6 weeks to generate cells with short telomeres. These
cells with short telomeres were then exposed to 1.0 μM of
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Figure 5 Inhibition of DNA-PKcs and telomerase increases cell death. (A) Greatest reduction in cell viability was observed following dual
inhibition of telomerase and DNA-PKcs with 1.0 μM MST-312 and 10 μM NU7026 respectively for 48 hours in MO59K cells. (B) Synergistic reduction in
cell number observed in MST-312 and NU7026 treated cells for one week determined by trypan blue exclusion assay. *P-value <0.05 when compared
to untreated controls. (C) Partial metaphase spreads from MO59K cells displaying chromosomes stained for telomeres (red) and centromeres (green)
with chromosomal fusion doublets (1), absence of telomere signals (2), different telomere intensity between sister chromatids (3). (D) Number aberrant
telomeres per cell in DNA-PKcs inhibited MO59K cells after 1.0 μM MST-312 treatment for 1 week.
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long telomeres. As demonstrated in Figure 6B, brain
tumour cells pre-treated with 0.5 μM of MST-312 (short
telomeres) showed smaller decrease in cell viability as
compared to brain tumour cells without MST-312 pre-
treatment (long telomeres). Significant reduction in cell
viability was only observed in MST-312 pre-treated
KNS60 cells as compared to control cells. More import-
antly, by suppressing DNA-PKcs activity along with tel-
omerase inhibition, the greatest decrease in cell survival
was observed in all brain tumour cells (Figure 6B).
Discussion
Despite harbouring massive genome instability, majority
of tumour cells continue to proliferate due to activation
of telomerase and subsequent telomere stabilisation [14],
In this study, we demonstrated the involvement of DNA-
PKcs in DDR pathway following telomerase inhibition inbrain tumour cells. Inhibition of telomerase using MST-
312 has been shown to induce telomere shortening
and impairment of cell proliferation (19). In addition,
a study on lung cancer cells revealed that acute tel-
omerase inhibition with MST-312 induced DNA dam-
age [37]. Similarly, we observed DNA damage and cell
cycle arrest (Figure 3A-D) following acute telomerase
inhibition. Continual exposure of brain tumour cells to
telomerase inhibition led to gradual telomere shortening
(Figure 2A). However, shortened telomeres were more re-
sistant to telomerase inhibition mediated growth reduction
(Figure 6B-D). It has been reported that short telomeres
initiate telomere recombination in tumour cells [38] and
such recombination can occur in telomerase-positive
cells following telomere dysfunction [39]. Although we
did not evaluate the mode of telomere maintenance in
brain tumour cells after 6 weeks of MST-312 treat-
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Figure 6 Activation of DNA-PKcs in MST-312 treated cells and cell survival in brain tumours cells following dual inhibition. (A) DNA-PKcs
activation in MST-312 treated cells determined by western blot analysis following 1.0 μM MST-312 and/or 10 μM NU7026 treatments. Increase in
the level of phospho-DNA-PKcs was seen in MO59K and KNS60 cells. On the contrary, minimal changes in the level phospho-DNA-PKcs were
observed in ONS76 cells. Representative images from two independent experiments are shown (B) Cell survival determined in cells pre-treated
with or without low dose MST-312 (0.5 μM) for 6 weeks following which cells were re-plated and treated with MST-312 (1.0 μM) and NU7026
DNA-PKcs inhibition (10.0 μM) for further 48 hours. Combined inhibition of telomerase and DNA-PKcs by MST-312 and NU7026 had the significant
reduction in percentage of viable cells for both cells that were pre-treated with a low concentration (0.5 μM) of MST-312 for 6 weeks (6WK) and cells
that were not pre-treated. Data represent mean ± SE from 3 independent experiments. *P-value <0.05 when comparing dual inhibited cells to
telomerase- inhibited cells for 48 hours. Red star P-value <0.05 when comparing dual inhibited treated cells to telomerase- inhibited cells in
pre-MST-312 treated cells.
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tenance by telomerase and recombination can co-exist
in cells [40].
More importantly, we uncover a link between telomere
dysfunction and chemosensitivity specifically towards
agents that inhibit DNA repair pathway, providing alter-
natives to overcome problems associated with long-term
exposure to telomerase inhibitors. The sensitizing effects
of DNA repair protein are more pronounced in rapidly
dividing cells like tumour cells [41] and a recent study
has also shown that DNA-PKcs inhibition sensitises
breast cancer cells to radiation via telomere capping dis-
ruption [42]. In this study, telomerase inhibition in brain
tumour cells showed impairment of HR pathway (Table 1)suggesting that DSBs could potentially be repaired by
NHEJ. Consistent with this, we observed phosphoryl-
ation of DNA-PKcs in brain tumour cells following
telomerase inhibition (Figure 6A) and genetic ablation
or pharmacological inhibition of DNA-PKcs in glio-
blastoma cells led to compromised DSBs repair, in-
creased telomere dysfunction and greater cell death
(Figures 4 and 5). Dual inhibition of DNA-PKcs and
telomerase in glioblastoma, medulloblastoma cells and
telomerase-negative osteosarcoma cells, U2OS showed
that telomerase-positive brain tumour cells were sensi-
tive to such combinatorial approach as compared to
U2OS cells. These data suggest that cells with impaired
DNA-PKcs activity appear to enhance a pre-existing
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with MST-312, leading to accumulation of unrepaired
DSBs and reduced cell proliferation (Figures 3 and 6).
In addition, MST-312 had relatively minimal effect in
non-cancerous, cell lines, MCF10A and MRC-5 (data
not shown).
It is important to note that in medulloblastoma cells,
ONS76, we did not detect activation of DNA-PKcs
following acute telomerase inhibition. In comparison
to glioblastoma cells, the relative decrease in telomer-
ase activity was lower in medulloblastoma cells. This
could possibly explain the lower level of DSBs induced
(Figure 3B). Differential gene expression detected be-
tween glioblastoma and medulloblastoma cells clearly
suggest some variation in the downstream effects of tel-
omerase inhibition in these brain tumour cells. The gen-
etic background of tumour cells also needs to be assessed
as this possibility influences the outcome of treatments.
For example, different status of p53 might have influ-
enced the opposite expression profiles of mitochondrial
function regulators genes PGC-1α and PGC-1β in our
study.
Conclusion
Our findings suggest the potential of targeting telomer-
ase and DNA-PKcs as an alternative way for improving
tumour radiotherapy. In addition, we showed that such
therapeutic approach alleviate problems associated with
using telomerase inhibitors alone. Enhanced cytotoxicity
observed in both types of brain tumour cells following
combined inhibition of telomerase and DNA-PKcs dem-
onstrated that this approach may not be cell-type spe-
cific. It is possible that DNA-PKcs inhibition impairs
the DNA-PKcs-mediated formation of the end-capping
structure at telomeres. This impairment may contribute
to telomere dysfunction following telomerase inhibition
and compromise the capacity of brain tumour cells to
maintain the already complex and unstable genome in-
tegrity. We have also seen that the absence of DNA-
PKcs (MO59J cells or DNA-PKcs targeted siRNA treated
MO59K cells) showed decreased expression of TERT
(data not shown), suggesting a possibility of a cross talk
between these two proteins in the process. However, fur-
ther studies using in vivo models are warranted and ideal
to test the efficacy of such strategy in management of
brain tumour cells.
Methods
Cell types and cell culture
Human glioblastoma multiforme cells MO59K (CRL-
2365) and MO59J (CRL-2366) (American Type Culture
Collection, USA) while glioblastoma multiforme cells
KNS60, and medulloblastoma cells ONS76 (Institute for
Fermentation, IF050357, and IF050355, respectively) wereobtained from Dr. Masao Suzuki, National Institute of
Radiological Sciences, Chiba, Japan. The cells were cul-
tured in Dulbecco’s Modified Eagles Medium (DMEM)
supplemented with 10% heat inactivated foetal bovine
serum (Hyclone, USA) and 100 U/ml of penicillin/
streptomycin (Gibco, USA). U2OS, ALT-positive osteo-
sarcoma cells (ATCC) were grown in 5A McCoy’s
medium, supplemented with 10% foetal bovine serum and
L-glutamine (Gibco, USA). All the cells were maintained in
a humidified 5% CO2 incubator at 37°C. Fresh medium
was added after every 2 days and the cell density was kept
below 80% confluence.
Drug treatment
Stock solution of MST-312 (Sigma, USA) [19] and DNA-
PKcs inhibitor, NU7026 (Calbiochem, USA) were prepared
in dimethyl sulfoxide (DMSO) and suitable working con-
centrations were made from the stock using complete
medium. For short- term experiments, cells were treated
with MST-312 and NU7026 for 48 hours. 10 μM of
NU7026 was used in this study as previous report has
shown that DNA-PKcs activity is completely inhibited at
this dose [43].
Telomere repeat amplification protocol (TRAP)
Brain tumour cells were treated with 0–5 μM MST-312
for 48 hours and telomerase activity detection was per-
formed with the commercially available TRAPeze® XL
Telomerase Detection Kit (Chemicon International, USA).
All steps were done according to the manufacturer’s in-
structions. Total protein was extracted from the cell pellet
by incubating in CHAPS lysis buffer for 30 minutes on ice.
Samples were spun at maximum speed at 4°C for 20 mi-
nutes to collect the supernatant. Protein quantification
was carried out using Bradford method and 1.5 μg protein
was treated with 1 ml/ml RNase inhibitor to eliminate
RNase before performing PCR reaction.
Telomere restriction fragment (TRF) length analysis
Following treatment of brain tumour cells with 0.5 μM
MST-312, DNA extraction was performed according to
the manufacturers’ protocol using DNeasy Tissue Kit
(Qiagen, USA). The telomere restriction fragment length
analysis assay was performed using Telo-TAGGG Length
Assay Kit (Roche Applied Science, USA). Kodak Gel im-
aging system and the Kodak imaging software was used
to calculate the quantitative measurements of the mean
TRF length.
Alkaline single cell Gel electrophoresis assay
Following treatments with 1.0 μM MST-312, cells
were harvested and resuspended in Hank’s Balanced
Salt Solution (Sigma) with 10% DMSO and 0.5 M EDTA.
The cell suspension was then suspended in 0.7% low
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to comet slides (Trevigen, USA). The cells were then
lysed in lysis solution containing 2.5 M NaCl, 100 mM
pH 8.0 EDTA, 10 mM Tris–HCl, 1% Triton–X at 4°C for
1 hour. Denaturation was carried out for 40 minutes, in
chilled alkaline electrophoresis buffer (pH 13.0-13.7).
Electrophoresis was subsequently carried out for 20 mi-
nutes. Slides were immersed in neutralization buffer
(500 mM Tris–HCl, pH 7.4), dehydrated, dried and
stained with SYBR Green dye (Trevigen) and scored with
Comet Analysis Software (Metasystems, Germany). The
images were captured using Zeiss Axioplan 2 imaging
fluorescence microscope (Carl Zeiss, Germany) equipped
with triple band filter. One hundred cells were randomly
selected and analysed. The extent of DNA damage was
expressed as tail moment, which corresponded to the
fraction of the DNA in the tail of the comet.
Immunofluorescence
Briefly, 5 × 104 brain tumour cells were plated in cover
slips in six well plates and grown for 48 hours in the
presence of 1.0 μM MST-312. Cells were fixed in 4%
paraformaldehyde and permeabilise in 0.1% Triton-X-
100. Following incubation with anti-phospho-H2AX
(Ser139) (Upstate, biotechnology) diluted in PBS with
4% FCS and 0.1% Triton X-100. Cells were washed and in-
cubated with FITC-conjugated anti-mouse secondary anti-
body (1:500) secondary antibodies at room temperature in
the dark for one hour. Subsequent washes were also con-
ducted in the dark. The cover slips were sufficiently dried
prior to mounting them onto slides containing Vectashield
mounting media with DAPI (Vector laboratories). One
hundred cells were randomly selected and screen for the
present of foci in each experiments. For the detection of
telomere dysfunction induced foci (TIF), cells were fixed
as described above with the following changes. Incubation
with mouse monoclonal anti- phosphor-H2AX (Millipore)
(1:300) was carried out overnight at 4°C, followed by incu-
bation with goat poly anti-TRF2 (Santa Cruz)(1:300)
for 1 hour incubation at room temperature. Goat anti-
mouse Texas Red (Invitrogen) (1:600) and rabbit anti-
goat Fluorescein (Vector Laboratories) were added and
incubated for 1 hour at room temperature. Images
were captured using a Zeiss Axioplan Imaging fluorescent
microscope with 63 × objective and are processed using
Adobe Photoshop CS2 (Adobe Systems Incorporated,
USA) for clarity and illustration.
Cell viability assay
A total of 1 × 104 cells per well were plated in transpar-
ent 24-well plates (Corning, Costar, USA) and treated
with various concentration of MST-312 (0–5 μM) and/or
10 μM NU7026 for 48 hours. Cell viability was measured
using CellTiter-Glo® luminescent cell viability assay(Promega, USA) according to the manufacturer’s instruc-
tions with some modifications. Briefly, the CellTiter-Glo®
reagent was added to cell culture and the mixture were
then transferred to white opaque walled 96-well plates
(Corning, Costar, USA) for measurement of luminescence
using plate reader (Tecan, Switzerland). Cell viability is
expressed as percentage of untreated controls.
Cell proliferation assay
About 1 × 104 cells per well were plated in transparent
12-well plates (Corning, Costar, USA) and 0.5 μM or
1.0 μM of MST-312 and/or 10 μM of NU7026 were
added. Fresh drug was added every 72 hours and cell
proliferation was determined with trypan blue exclusion
assay after indicated number of days.
Cell cycle analysis
Following 0–2.0 μM MST-312 treatment, cells were har-
vested, washed in 0.1% BSA: PBS, fixed in 70% ethanol:
1 × PBS, and stained with propidium iodide (Sigma, USA):
RNase A (Roche, USA) (2 mg propidium iodide and 2 mg
RNaseA/100 mL 0.1% BSA in 1 × PBS). Samples were ana-
lysed by flow cytometry (FACSCalibur™, Becton Dickinson,
USA) at 488 nm excitation λ and 610 nm emission λ. A
total of 10,000 events were captured and data obtained was
analysed using Summit 4.3 software. The proportion of
cells in different stages of cell cycle is expressed in terms of
percentage of total cells analysed.
Western blot analysis
Total cellular proteins were isolated following a 48 hour-
treatment with 1.0 μM of MST-312 and/or 10 μM of
NU7026, using RIPA (radio-immunoprecipitation assay)
buffer (1% nonidet P-40, 1% sodium deoxycholate, 0.1%
SDS, 0.15 M NaCl, 0.01 M sodium phosphate, 2 mM
EDTA, 50 mM sodium fluoride, 0.2 mM sodium vanad-
ate and 100 U/ml aprotinin, pH 7.2) from control and
treated cells. The whole cell lysate was recovered by cen-
trifugation at 14,000 rpm for 10 minutes. Protein con-
centration was determined by the bicinchoninic acid
method using an assay kit (Pierce Biotechnology, USA)
with bovine serum albumin as a standard. Western blot
analyses of, DNA-PKcs, p-DNA-PKcs(Ser2056), (phospho
DNA-PKcs, Abcam, UK,1:1000) hTERT (Epitomics, USA),
and β-actin were performed using specific antibodies from
Santa Cruz Biotechnology, USA unless otherwise stated.
Peptide nucleic acid fluorescence in situ hybridisation
(PNA-FISH) analysis
For cytogenetic analysis, MO59K cells were treated with
1.0 μM of MST-312 and/or 10 μM of NU7026 for 1 week
and cells were arrested at mitosis by treatment with col-
cemid (0.1 mg/ml). Cells were subsequently incubated
with a hypotonic solution of potassium chloride at 37°C
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Fluorescence in situ hybridisation (FISH) was performed
using telomere sequence-specific peptide nucleic acid
(PNA) probe labelled with Cy3 as described [44,45].
Metaphase spreads were captured using Zeiss Axioplan
2 Imaging fluorescence microscope and analysed using
ISIS Software (Metasystems, Germany) for telomere-
mediated chromosome alterations.
Gene expression analysis
Following treatment with 1.0 μM of MST-312 for
48 hours, the total RNA was extracted from KNS60
and ONS76 cells using QIAmp RNA Blood Mini Kit
(Qiagen, Hilden, Germany). The extracted RNA was quan-
tified using NanoDrop 1000 (Thermo Scientific, USA).
RNA integrity was checked using Bio-Analyzer (Agilent
Technologies, Inc., USA). Five hundred nanograms of ex-
tracted RNA from each sample were used for gene expres-
sion study. TotalPrep RNA Amplification Kit (Ambion
Inc., TX, USA) was used for cRNA amplification process.
The biotinylated amplified RNA thus generated was used
for hybridization with HumanRef8 V3.0, Human Whole-
Genome Expression BeadChips (Illumina Inc., USA)
for 16 hours at 58°C. After the incubation period, the
arrays were washed and stained with Streptavidin-Cy3
(GE Healthcare, Bio-Sciences, UK). Illumina Bead Array
Reader was used to scan the arrays. The array data thus
obtained after scanning was imported and analysed using
Partek® Genomics Suite™ (Partek GS) (Partek Incorporated,
MO, USA).
Statistical analysis
Statistical significance in the data sets was assessed by
Student’s t-test (Microsoft Corporation, USA) and two-
way ANOVA using Graphpad Prism. The difference was
considered to be statistically significant when p < 0.05.
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